TBTC Launches CRUSH-TB trial
CDC’s Tuberculosis Trials Consortium (TBTC) has recently launched the CRUSH-TB trial, which aims to identify new combinations of drugs to shorten treatment of active TB disease. Kelly Dooley, MD, PhD, MPH, Director, Division of Infectious Diseases, is a Protocol Chair for this new study.
Read more from CDC’s TB Notes newsletter:
Results Published: Randomized Trial for Self-administered vs DOT Once-Weekly Isoniazid and Rifapentine Treatment of Latent TB Infection
Results from the iAdhere trial conducted through the TB Trials Consortium have been published in the Annals of Internal Medicine. This randomized trial aimed to compare treatment completion and safety of once-weekly isoniazid and rifapentine by self-administration versus direct observation. Enrollment sites were located in the US, Spain, Hong Kong, and South Africa; Vanderbilt and the Metro Nashville Health Department participated in enrollment.